Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Advance Pharmaceutical Completes Enrollment for HTI-320 Clinical Trial

publication date: Oct 6, 2015
Advance Pharmaceutical of Hong Kong completed enrollment for the clinical trial of BTI-320, also known as Sugardown® , at the Chinese University of Hong Kong (CUHK). The clinical trial enrolled 60 pre-diabetic patients and is a single-center, 16-week, randomized, double-blind pilot study designed to evaluate the efficacy and safety of BTI-320 in the treatment of high risk subjects with pre-diabetes. It is supplemental to an on-going separate clinical trial being conducted in mainland China. More details....

Share this with colleagues:  

references 

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital